Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GH Research PLC stock logo
GHRS
GH Research
$27.65
-1.5%		$25.03
$11.32
▼
$31.00
$1.90B1.28302,632 shs21,626 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$14.16
-0.1%		$14.89
$12.66
▼
$21.50
$1.84B2.08232,529 shs12,890 shs
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
$37.91
-1.2%		$37.83
$6.09
▼
$57.14
$1.90B0.7871,744 shs21,547 shs
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$5.09
+2.4%		$5.32
$4.75
▼
$12.25
$482.97M1.7751,136 shs697 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GH Research PLC stock logo
GHRS
GH Research
0.00%+2.90%+3.92%+35.54%+104.29%
Mesoblast Limited stock logo
MESO
Mesoblast
0.00%-7.45%-1.46%-9.97%-6.59%
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
0.00%-3.32%-0.05%+9.28%+469.86%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
0.00%+3.97%-4.79%-7.10%-31.16%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GH Research PLC stock logo
GHRS
GH Research
$27.65
-1.5%		$25.03
$11.32
▼
$31.00
$1.90B1.28302,632 shs21,626 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$14.16
-0.1%		$14.89
$12.66
▼
$21.50
$1.84B2.08232,529 shs12,890 shs
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
$37.91
-1.2%		$37.83
$6.09
▼
$57.14
$1.90B0.7871,744 shs21,547 shs
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$5.09
+2.4%		$5.32
$4.75
▼
$12.25
$482.97M1.7751,136 shs697 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GH Research PLC stock logo
GHRS
GH Research
0.00%+2.90%+3.92%+35.54%+104.29%
Mesoblast Limited stock logo
MESO
Mesoblast
0.00%-7.45%-1.46%-9.97%-6.59%
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
0.00%-3.32%-0.05%+9.28%+469.86%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
0.00%+3.97%-4.79%-7.10%-31.16%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GH Research PLC stock logo
GHRS
GH Research
2.67
Moderate Buy$40.7847.51% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
2.50
Moderate BuyN/AN/A
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
2.50
Moderate Buy$37.33-1.51% Downside
Valneva SE Sponsored ADR stock logo
VALN
Valneva
2.20
Hold$11.98135.27% Upside

Current Analyst Ratings Breakdown

Latest VALN, GHRS, NBTX, and MESO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/27/2026
GH Research PLC stock logo
GHRS
GH Research
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$44.00
7/27/2026
GH Research PLC stock logo
GHRS
GH Research
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$44.00
7/17/2026
GH Research PLC stock logo
GHRS
GH Research
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Mesoblast Limited stock logo
MESO
Mesoblast
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/15/2026
GH Research PLC stock logo
GHRS
GH Research
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
6/18/2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/4/2026
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$37.00 ➝ $46.00
5/19/2026
GH Research PLC stock logo
GHRS
GH Research
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$70.00 ➝ $65.00
5/18/2026
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
5/15/2026
GH Research PLC stock logo
GHRS
GH Research
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GH Research PLC stock logo
GHRS
GH Research
N/AN/AN/AN/A$4.51 per shareN/A
Mesoblast Limited stock logo
MESO
Mesoblast
$17.20M106.89N/AN/A$4.67 per share3.03
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
$29.64M64.73N/AN/A($1.97) per share-19.24
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$156.33M3.09N/AN/A$1.39 per share3.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GH Research PLC stock logo
GHRS
GH Research
-$48.26M-$0.92N/AN/AN/AN/A-19.36%-18.73%8/6/2026 (Estimated)
Mesoblast Limited stock logo
MESO
Mesoblast
-$102.14M-$0.28N/AN/AN/AN/AN/AN/A9/4/2026 (Estimated)
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
-$27.11MN/AN/A379.05N/AN/AN/AN/A9/29/2026 (Estimated)
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$130.33M-$1.87N/A2.69N/A-88.87%-107.63%-33.02%8/13/2026 (Estimated)

Latest VALN, GHRS, NBTX, and MESO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$0.1887N/AN/AN/A$43.86 millionN/A
8/6/2026Q2 2026
GH Research PLC stock logo
GHRS
GH Research
-$0.3040N/AN/AN/AN/AN/A
5/14/2026Q1 2026
GH Research PLC stock logo
GHRS
GH Research
-$0.27-$0.31-$0.04-$0.31N/AN/A
5/13/2026Q1 2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$0.1485-$0.42-$0.2715-$0.42$54.69 million$36.16 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
GH Research PLC stock logo
GHRS
GH Research
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
N/AN/AN/AN/AN/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GH Research PLC stock logo
GHRS
GH Research
N/A
34.13
34.13
Mesoblast Limited stock logo
MESO
Mesoblast
0.10
1.58
1.41
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
N/A
1.09
1.09
Valneva SE Sponsored ADR stock logo
VALN
Valneva
2.14
2.14
1.60

Institutional Ownership

CompanyInstitutional Ownership
GH Research PLC stock logo
GHRS
GH Research
56.90%
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
38.81%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
11.39%

Insider Ownership

CompanyInsider Ownership
GH Research PLC stock logo
GHRS
GH Research
41.60%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
3.45%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
14.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
GH Research PLC stock logo
GHRS
GH Research
1068.61 millionN/AOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
80129.88 million105.46 millionOptionable
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
10050.62 million48.87 millionNot Optionable
Valneva SE Sponsored ADR stock logo
VALN
Valneva
70094.89 million80.74 millionNot Optionable

Recent News About These Companies

Valneva SE Sponsored ADR (NASDAQ:VALN) Receives Consensus Rating of "Hold" from Analysts
July 31 at 6:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/valneva-se-sponsored-adr-nasdaqvaln-receives-consensus-rating-of-hold-from-analysts-2026-07-31/
Valneva SE termine en hausse
July 24, 2026  |  boursier.comB
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331572/0/en/valneva-to-report-first-half-2026-consolidated-financial-results-on-august-13-2026.html
Valneva (NASDAQ:VALN) Shares Gap Up - What's Next?
July 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/valneva-nasdaqvaln-shares-gap-up-whats-next-2026-07-13/
Valneva SE Sponsored ADR
July 11, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/VALN
Experimental vaccine shows promise against dangerous intestinal illness
July 7, 2026  |  msn.comhttps://www.msn.com/en-us/health/health-news/experimental-vaccine-shows-promise-against-dangerous-intestinal-illness/ar-AA27m9Id
If a Lyme disease vaccine gets approved, how would it go over? We asked hunters
June 28, 2026  |  msn.comhttps://www.msn.com/en-us/pets-and-animals/wildlife/if-a-lyme-disease-vaccine-gets-approved-how-would-it-go-over-we-asked-hunters/ar-AA26H5tl
New research may lead to a vaccine against severe diarrhea
June 26, 2026  |  medicalxpress.comM
Valneva SE (VALN) Shareholder/Analyst Call - Slideshow
June 25, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4917923-valneva-se-valn-shareholder-analyst-call-slideshow
Research may help pave the way for new vaccine targeting diarrheal disease
June 25, 2026  |  news-medical.netN
Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript
June 25, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4917744-valneva-se-valn-shareholder-analyst-call-prepared-remarks-transcript
Valneva Announces Successful Outcome of its Annual General Meeting
June 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/25/3317784/0/en/valneva-announces-successful-outcome-of-its-annual-general-meeting.html
Valneva Announces Availability of Documentation for its Annual General Meeting
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3306502/0/en/valneva-announces-availability-of-documentation-for-its-annual-general-meeting.html
VALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026
June 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/valneva-declaration-shares-voting-rights-160000347.html
Valneva annonce sa participation à des conférences investisseurs aux États-Unis et en Europe
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3303079/0/fr/valneva-annonce-sa-participation-%c3%a0-des-conf%c3%a9rences-investisseurs-aux-%c3%89tats-unis-et-en-europe.html
Valneva to Participate at U.S. and European Investor Conferences in June
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3303079/0/en/valneva-to-participate-at-u-s-and-european-investor-conferences-in-june.html
Valneva SE 2026 Q1 - Results - Earnings Call Presentation
May 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4905724-valneva-se-2026-q1-results-earnings-call-presentation
Valneva SE (VALN) Q1 2026 Earnings Call Transcript
May 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4904015-valneva-se-valn-q1-2026-earnings-call-transcript
Valneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ...
May 13, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/valneva-se-inrlf-q1-2026-230018488.html
Valneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccines
May 13, 2026  |  fiercebiotech.comF
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3293636/0/en/valneva-reports-first-quarter-2026-financial-results-and-provides-corporate-updates.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

GH Research stock logo

GH Research NASDAQ:GHRS

$27.64 -0.43 (-1.51%)
As of 10:06 AM Eastern
This is a fair market value price provided by Massive. Learn more.

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$14.16 -0.01 (-0.10%)
As of 10:06 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Nanobiotix stock logo

Nanobiotix NASDAQ:NBTX

$37.90 -0.48 (-1.24%)
As of 10:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Valneva stock logo

Valneva NASDAQ:VALN

$5.09 +0.12 (+2.41%)
As of 10:02 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas